会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 6. 发明申请
    • CANCER THERAPY
    • 癌症治疗
    • US20110269699A1
    • 2011-11-03
    • US13124838
    • 2008-10-24
    • Mitchell KeeganRicky W. JohnstoneAndrea NewboldLeonie Cluse
    • Mitchell KeeganRicky W. JohnstoneAndrea NewboldLeonie Cluse
    • A61K38/15A61P35/00C12Q1/68C12N5/09C12Q1/02
    • A61K38/15
    • The invention provides therapy for treating cancers, such as Bcl-2+ cancers, and Bcl-XL− cancers, and other neoplasms, using romidepsin. The invention provides, inter alia, methods of treating lymphomas, e.g., lymphomas characterized by one or more of Bcl-2 expression, lack of overexpression of Bcl-XL, lack of overexpression of P-glycoprotein, with romidepsin. In some embodiments, the lymphoma is a cutaneous T cell lymphoma. In some embodiments, the lymphoma is a peripheral T cell lymphoma. Romidepsin can be administered a dosages ranging from 0.5 mg/m2 to approximately 28 mg/m2 (e.g., from 1 mg/m2 to 15 mg/m2, from 4 mg/m2 to 15 mg/m2, from 8 mg/m2 to 14 mg/m2, or from 4 mg/m2 to approximately 10 mg/m2). Romidepsin can be administered with a second agent, such as a cytotoxic agent, a steroidal agent, a proteasome inhibitor, or a kinase inhibitor.
    • 本发明提供用于治疗癌症如Bcl-2 +癌症和Bcl-XL-癌症以及其它肿瘤的治疗方法,其使用罗非替克。 本发明尤其提供了治疗淋巴瘤的方法,例如特征在于Bcl-2表达中的一种或多种,​​Bcl-XL的过表达缺乏,罗糖蛋白缺乏P-糖蛋白过表达的淋巴瘤。 在一些实施方案中,淋巴瘤是皮肤T细胞淋巴瘤。 在一些实施方案中,淋巴瘤是外周T细胞淋巴瘤。 罗非曲汀可以以0.5mg / m 2至约28mg / m 2(例如,1mg / m 2至15mg / m 2,4mg / m 2至15mg / m 2,8mg / m 2至14 mg / m 2,或4mg / m 2至约10mg / m 2)。 罗非替西可以与第二药剂如细胞毒素剂,甾体药物,蛋白酶体抑制剂或激酶抑制剂一起施用。
    • 8. 发明申请
    • Combination therapy
    • 联合治疗
    • US20090105200A1
    • 2009-04-23
    • US12009867
    • 2008-01-23
    • Mitchell KeeganSteven Grant
    • Mitchell KeeganSteven Grant
    • A61K31/56A61K31/395C12N5/02A61P35/04A61K31/4965
    • A61K38/07A61K31/69A61K38/15A61K45/06A61K2300/00
    • The invention provides a combination therapy for treating cancer and other neoplasms including romidepsin and a proteasome inhibitor. When administered together, romidepsin and a proteasome inhibitor (e.g., bortezomib) interact synergistically to selectively kill malignant cells at low (nanomolar) concentrations. The effect is particularly pronounced in malignant hematological cells (e.g., leukemia, lymphoma, multiple myeloma). The combination has also been found useful in treating bortezomib-resistant cancers and steroid-resistant cancers. The invention provides methods of killing malignant cells in vitro and in vivo. Pharmaceutical compositions, preparations, and kits including romidepsin and a proteasome inhibitor are also provided.
    • 本发明提供了治疗癌症和其它肿瘤的组合疗法,其中包括罗非替克和蛋白酶体抑制剂。 当一起施用时,罗非替西和蛋白酶体抑制剂(例如硼替佐米)协同作用以选择性地以低(纳摩尔)浓度杀死恶性细胞。 这种作用在恶性血液细胞(例如白血病,淋巴瘤,多发性骨髓瘤)中特别明显。 已经发现该组合可用于治疗硼替佐米耐药性癌症和类固醇抗性癌症。 本发明提供在体外和体内杀死恶性细胞的方法。 还提供了药物组合物,制剂和试剂盒,包括罗维切蛋白酶和蛋白酶体抑制剂。